



Affymetrix Inc.

Media Contact:

Andrew Noble
Associate Director, Corporate Communications
408-731-5571

Investor Contact:

Doug Farrell
Vice President, Investor Relations
408-731-5285

Affymetrix Completes Acquisition of USB Corporation

USB reagent platform complements Affymetrix' current product portfolio and can be applied to a broad variety of new and emerging applications

SANTA CLARA, Calif., January 31, 2008 – Affymetrix Inc. (Nasdaq: AFFX) today announced the completion of its acquisition of USB Corporation, a privately held Cleveland, Ohio-based company that develops, manufactures and markets an extensive line of molecular biology and biochemical reagent products. In connection with the completion of the acquisition, USB stockholders received approximately \$75 million in cash.

"The acquisition of USB immediately expands our talent base, enhances our whole-product solution offering and creates new, long-term growth opportunities," said Kevin King, president of Affymetrix. "Our customers will now be able to take advantage of a stronger portfolio of GeneChip® products today and the incorporation of next-generation sequencing reagents into the products of tomorrow."

USB is a leading developer, manufacturer and supplier of enzymes, reagents and kits for life sciences research and industrial applications. The company's offerings are grouped into three major product lines consisting of molecular biology enzymes and kits, biochemical reagents and products used in membrane protein research applications. The company history extends back to the 1970s, known then as United States Biochemical. In 1993, United States Biochemical was purchased by Amersham Life Science, a company that merged in 1997 with Swedish-owned Pharmacia Biotech. The current USB Corporation was founded in 1998 after members of the senior management team acquired the three original product lines back from Amersham Pharmacia Biotech. USB has approximately 100 employees who will be joining Affymetrix.

Affymetrix' management team will host a conference call on January 31, 2008 at 2 p.m. PT to review its operating results for the fourth quarter and fiscal year 2007. The company will also discuss the impact of this acquisition on this call. A live webcast can

be accessed by visiting the Investor Relations section of the Company's website at www.affymetrix.com. In addition, investors and other interested parties can listen by dialing domestic: (866) 500-AFFX, international: (706) 643-2771.

About Affymetrix

Affymetrix GeneChip® microarray technology is the industry-standard tool for analyzing complex genetic information. After inventing microarray technology in the late 1980s, Affymetrix scientists have been dedicated to developing innovative products that provide researchers with a more complete view of the genome. These products continue to accelerate genetic research and enable scientists to develop diagnostics and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases.

Today, Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies, as well as leading academic, government and not-for-profit research institutes. More than 1,600 systems have been shipped around the world and more than 10,500 peer-reviewed papers have been published using the technology.

Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Sacramento, Calif., Cleveland, Ohio and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit: www.affymetrix.com.

Forward-looking Statements

All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies" or the like. Such statements, including Affymetrix' financial expectations and Affymetrix' expectations that the acquisition will accelerate product development and commercialization and drive microarray sales, are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected. These risks and uncertainties include, but are not limited to: (i) the inability of Affymetrix to successfully integrate USB's business into its existing business in a timely and non-disruptive manner; (ii) the inability of Affymetrix to achieve expected synergies from the acquisition, including revenue synergies; (iii) difficulty in retaining USB's employees following the acquisition, including key personnel; (iv) unexpected costs and charges associated with the acquisition, including the write-off of intangible assets; (v) the possibility of an adverse impact to Affymetrix' and USB's businesses as a result of the acquisition or uncertainty surrounding the acquisition; and (vi) other risks described in Affymetrix' Form 10-K for the year ended December 31, 2006, and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

NOTE: Affymetrix, the Affymetrix logo and GeneChip® are registered trademarks owned or used by Affymetrix Inc.

###